9-Methoxycamptothecin induces proliferating cell nuclear antigen associated factor 15 mediated proliferation inhibition, DNA damage, and apoptosis in melanoma cells [0.03%]
10-甲氧基喜树碱通过诱导核增殖抗原相关蛋白15介导的黑色素瘤细胞生长抑制、DNA损伤和凋亡发挥作用
Yacong Ji,Chongyang Li,Han Hao et al.
Yacong Ji et al.
Melanoma is one of the most lethal forms of skin cancer, driving continuous research efforts to discover effective therapeutic strategies. Phytochemicals are promising for antimelanoma drug development because of their multitarget bioactivi...
Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report [0.03%]
一例罕见NF1相关少突胶质瘤病例的多模式治疗：硫替派、贝伐珠单抗、天尼平和通拉美替尼联合疗法
Shizhen Zhou,Yanfei Chen,Guoliang Gao et al.
Shizhen Zhou et al.
Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder associated with central nervous system gliomas, most frequently optic pathway gliomas; however, oligodendrogliomas in the setting of NF1 are exceedingly rare, with no pr...
Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial [0.03%]
替雷利珠单抗联合化疗治疗晚期HIV阳性非小细胞肺癌患者Ⅰ期临床研究：与特瑞普利单抗和化疗对照试验初步分析
Yaping Quan,Hao Li,Zhengjie Liang et al.
Yaping Quan et al.
Immune checkpoint inhibitors (ICIs) are a standard treatment for advanced non-small-cell lung cancer (NSCLC), but limited data exist regarding their use in patients with HIV-positive. This study evaluated the efficacy and safety of ICI-base...
Locoregional and symptomatic response to neoadjuvant dual HER2 blockade with chemotherapy in HER2-positive breast cancer: a pilot study [0.03%]
赫二阳性乳腺癌新辅助联合赫二阻断和化疗的新辅疗效及症状缓解的临床研究：一项初步探索性研究
Gurjeet Singh Chowdhary,Ankush Nayyar,Sridharan Vasudevan et al.
Gurjeet Singh Chowdhary et al.
Dual HER2 blockade with trastuzumab and pertuzumab in combination with chemotherapy has improved pathological complete response (pCR) rates in HER2-positive breast cancer in randomized trials. However, real-world pilot data on locoregional ...
PLCG2 promotes cell survival and mitophagy of small cell lung cancer via regulating VCP [0.03%]
PLCG2通过调节VCP促进小细胞肺癌细胞存活和线粒体自噬
Juan Jiang,Ju Zhu,Yin Xiao et al.
Juan Jiang et al.
Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer that is characterized by rapid growth. PLCG2 is an enzyme that plays a crucial role in intracellular signal transduction pathways. This study aims to discover the role...
Anti-CD19 antibody tafasitamab therapy for relapsed or refractory diffuse large B-cell lymphoma: a case series [0.03%]
抗CD19抗体tafasitamab治疗复发或难治性弥漫大B细胞淋巴瘤的疗效：一系列病例报告
Jianhua You,Wenting Chen,Zixun Yan et al.
Jianhua You et al.
Tafasitamab, an anti-CD19 mAb, has demonstrated promising efficacy in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in Western populations, but its use in Chinese patients has not been reported. This case series reports t...
Successful treatment with erlotinib plus ramucirumab in a patient with non-small-cell lung cancer harboring EGFR exon 20 insertion mutation [0.03%]
用于表皮生长因子受体外显子20插入突变非小细胞肺癌的厄洛替尼联合ramucirumab治疗取得成功
Koki Nakashima,Koji Yamaoka,Yukihiro Umeda et al.
Koki Nakashima et al.
As epidermal growth factor receptor (EGFR) exon 20 insertion mutations generally result in poor sensitivity to EGFR-tyrosine kinase inhibitors (TKIs), the administration of EGFR-TKIs is not recommended in non-small-cell lung cancer (NSCLC)....
Identifying novel triazole-containing histone deacetylase 1 antitumor inhibitors through molecular simulations and ADME/T profiling [0.03%]
基于分子模拟和ADMET性质筛选的组蛋白去乙酰化酶1新型抗肿瘤小分子抑制剂的研究与发现
Yan Tuo,Chao Li,Qing Wan et al.
Yan Tuo et al.
Histone deacetylase 1 (HDAC1), a pivotal epigenetic modulator, is critically involved in oncogenesis and serves as a promising target for anticancer drug discovery. In this study, 59 reported HDAC1 inhibitors were utilized to establish robu...
Histone lactylation promoted colorectal cancer progression by enhancing tumor necrosis factor transcription and served as a diagnostic biomarker [0.03%]
组蛋白乳酰化通过增强肿瘤坏死因子转录促进结直肠癌进展并用作诊断生物标志物
Shiyang Li,Xiufang Shi,Xiaoyue Zhou
Shiyang Li
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with unmet needs for early diagnostic biomarkers and therapeutic targets. Recent studies highlight the role of histone lactylation (H3K18la) in modulating...
A genome-wide screen identified ARHGAP35 as a regulator of regorafenib resistance in liver cancer [0.03%]
基因组广泛筛查确定ARHGAP35作为肝癌regorafenib耐药性的调节因子
Kun Chen,Miaomiao Zhang,Yuexin Liu et al.
Kun Chen et al.
Regorafenib, a multikinase inhibitor, is widely used to treat hepatocellular carcinoma. However, chemoresistance poses a significant challenge to its long-term efficacy. This study conducted a genome-wide CRISPR/Cas9 knockout screen in live...